Literature DB >> 902662

Use of saliva in monitoring carbamazepine medication in epileptic children.

H Bartels, H D Oldigs, E Günther.   

Abstract

In 17 children on carbamazepine medication alone and 15 children on combined drug regimens, carbamazepine levels were determined in paired samples of serum and mixed saliva by enzyme immunoassay. Carbamazepine levels in serum and saliva were highly correlated in within-patient and between patient series (r = 0.87--0.94). Salivary levels were altered to a minor and clinically insignificant degree by stimulation of saliva flow. Mean saliva/serum ratios, calculated from drug concentrations in saliva specimens collected without and with stimulation were 0.44--0.45 and 0.41--0.43, respectively. The saliva/serum ratio was independent of the serum carbamazepine level and was not affected by concomitant drug medication. The data indicate that measuring salivary levels by enzyme immunoassay is suitable for predicting serum carbamazepine levels. Thus, measurement of carbamazepine levels in mixed saliva samples obtained by a noninvasive technique is recommended for routine monitoring of carbamazepine medication in epileptic children.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902662     DOI: 10.1007/bf00443121

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  12 in total

1.  Anticonvulsant level in saliva, serum, and cerebrospinal fluid.

Authors:  A S Troupin; P Friel
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

Review 2.  Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring.

Authors:  B H Dvorchik; E S Vesell
Journal:  Clin Chem       Date:  1976-06       Impact factor: 8.327

3.  Use of saliva in therapeutic drug monitoring.

Authors:  M G Horning; L Brown; J Nowlin; K Lertratanangkoon; P Kellaway; T E Zion
Journal:  Clin Chem       Date:  1977-02       Impact factor: 8.327

4.  Studies on plasma protein binding of carbamazepine.

Authors:  E Di Salle; G M Pacifici; P L Morselli
Journal:  Pharmacol Res Commun       Date:  1974-04

5.  The concentration of carbamazepine (Tegretol R) in serum and in cerebrospinal fluid in patients with epilepsy.

Authors:  S I Johannessen; R E Strandjord
Journal:  Acta Neurol Scand Suppl       Date:  1972

6.  Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.

Authors:  A Rane; B Höjer; J T Wilson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

7.  Diphenylhydantoin, phenobarbital, and primidone in saliva, plasma, and cerebrospinal fluid.

Authors:  D Schmidt; J Kupferberg
Journal:  Epilepsia       Date:  1975-12       Impact factor: 5.864

8.  Phenytoin and phenobarbital concentrations in saliva and plasma measured by radioimmunoassay.

Authors:  C E Cook; E Amerson; W K Poole; P Lesser; L O'Tuama
Journal:  Clin Pharmacol Ther       Date:  1975-12       Impact factor: 6.875

9.  Plasma protein binding of carbamazepine.

Authors:  W D Hooper; D K Dubetz; F Bochner; L M Cotter; G A Smith; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

10.  Salivary phenytoin concentrations in epilepsy and in chronic renal failure.

Authors:  F Reynolds; P N Ziroyanis; N F Jones; S E Smith
Journal:  Lancet       Date:  1976-08-21       Impact factor: 79.321

View more
  10 in total

Review 1.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

Review 2.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

3.  A comparison of plasma and saliva levels of carbamazepine and phenytoin as monotherapy.

Authors:  N Callaghan; T Goggin
Journal:  Ir J Med Sci       Date:  1984-05       Impact factor: 1.568

4.  Saliva carbamazepine and phenytoin level monitoring.

Authors:  G W Rylance; T A Moreland
Journal:  Arch Dis Child       Date:  1981-08       Impact factor: 3.791

Review 5.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

6.  Correlation between the saliva and free serum concentration of phenobarbital in epileptic children.

Authors:  K Tokugawa; K Ueda; H Fujito; T Kurokawa
Journal:  Eur J Pediatr       Date:  1986-10       Impact factor: 3.183

Review 7.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

8.  Carbamazepine dose-frequency requirement in children.

Authors:  G W Rylance; T A Moreland; G M Butcher
Journal:  Arch Dis Child       Date:  1979-06       Impact factor: 3.791

Review 9.  Carbamazepine toxicity and poisoning. Incidence, clinical features and management.

Authors:  L Durelli; U Massazza; R Cavallo
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

10.  Deproteinization as a Rapid Method of Saliva Purification for the Determination of Carbamazepine and Carbamazepine-10,11 Epoxide.

Authors:  Ewelina Dziurkowska; Marek Wesolowski
Journal:  J Clin Med       Date:  2020-03-27       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.